JP Morgan upgrades Unum Gr to Overweight from Neutral, lowers price target to $90 from $98

JP Morgan upgraded Unum Group to Overweight from Neutral, lowering its price target to $90 from $98, an 8.2% decrease. The new target implies a 17.3% upside from the Nov 6 close of $76.75. Recent analyst price targets for Unum Group range from $85 to $102.

Original reporting
Published Nov 9, 2026, 12:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 12:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
JP Morgan upgrades Unum Gr to Overweight from Neutral, lowers price target to $90 from $98 — source image
Decision brief

The 30-second read

$UNMNeutralMed
01

Why it matters

The price target reduction may prompt short-term selling pressure, while the overweight rating could attract long-term interest.

02

Market read

Analyst upgrade with a lower price target provides a nuanced signal for traders evaluating Unum Group.

03

What to watch

Potential upcoming earnings or regulatory changes that could reverse the price target cut.

Relevance 7/10Novelty 6/10Timing: today

Background

JPMorgan's analyst action reflects a mixed view: rating upgrade but reduced price expectations.

Company-level read

Ticker impact

$UNMNeutralHigh confidence
Context

JPMorgan upgraded Unum Group to Overweight and cut its price target to $90 from $98.

Expected impact

likely modest downside as the lower target outweighs the rating upgrade

Evidence & confidence

Analyst price target cuts typically signal reduced valuation expectations, which can pressure the stock despite a positive rating.

Market effects

May slightly affect the insurance sector as analysts reassess valuation multiples.

Limited to U.S. markets where Unum trades.

Low

Counterpoint

The overweight rating could indicate confidence in fundamentals, suggesting a buying opportunity despite the lower target.

Key entities

  • JPMorgan

    Upgraded Unum Group to Overweight and lowered price target.

  • Unum Group

    Insurance provider receiving the analyst action.

Related articles

$UNMMed

Unum Group Stocks Climb 5.19% After JPMorgan Upgrade to Overweight

Unum Group (NYSE:UNM) shares rose 5.19% to $80.74 after JPMorgan upgraded it to Overweight, lowering its price target to $90. The firm cited attractive risk/reward despite lower estimates. Unum reported a Q3 net loss of $2.65 per share due to a $853 million investment loss, but adjusted operating income was $2.20 per share. Core premiums grew 4.7%, while US sales fell 8.5%. The company expects full-year adjusted operating income of $8.30 to $8.50 per share.

$UNMHigh

Unum Group Q3 Earnings Call Highlights

Unum Group (UNM) reported Q3 earnings, noting long-term disability claims 10% above expectations, driven by behavioral health. The company is implementing double-digit rate increases and expects full-year 2026 earnings of $8.30-$8.50 per share. Unum also completed a reinsurance transaction, reducing long-term care exposure by over 40%.

$UNMMedAI 8/10

Unum Group (UNM) (Q3 2026) Earnings Call Highlights: Disability Claims Surge Weighs

Unum Group (UNM) reported Q3 2026 earnings with mixed results. Core premiums grew 5%, and the company returned $1B to shareholders. However, earnings per share of $2.20 missed expectations due to higher disability claims. The group disability benefit ratio rose to 70.6%, and the full-year EPS outlook was revised to $8.30-$8.50. Management attributed the increase in claims to behavioral health issues and expects pricing actions to address the trend.

$UNMHighAI 9/10

Why is Unum stock crashing today?

Unum Group (UNM) stock fell 18.7% to $74.03 after reporting a Q3 2026 GAAP net loss of $419.7M, revenue shortfall of $360M, and adjusted EPS decline of 21%. Barclays cut its price target to $101. The drop is attributed to reinsurance-related charges, rising disability claims, and market focus on earnings deterioration.